Entera Bio (ENTX) Return on Capital Employed (2022 - 2026)

Entera Bio has disclosed Return on Capital Employed across 5 years of filings, most recently posting 96.79% for Q1 2026.

• Quarterly Return on Capital Employed fell 2363.0% year-over-year to 96.79% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 96.79% (down 2363.0% YoY) and the FY2025 annual result came in at 109.92%, down 797.0% from the prior year.
• Return on Capital Employed declined to 96.79% in Q1 2026, from 79.96% in the prior quarter.
• Over five years, Return on Capital Employed peaked at 56.67% in Q2 2025 and troughed at 133.67% in Q3 2023.
• A 5-year average of 93.1% and a median of 96.79% in 2026 frame the typical range for Return on Capital Employed.
• Annual changes were most pronounced in 2023 — Return on Capital Employed sank 4660 bps — and 2025, when it soared 5409 bps.
• Tracing ENTX's Return on Capital Employed over 5 years: stood at 100.19% in 2022, then gained by 2 bps to 97.98% in 2023, then plunged by 33 bps to 130.55% in 2024, then surged by 39 bps to 79.96% in 2025, then dropped by 21 bps to 96.79% in 2026.
• Business Quant data shows ENTX's Return on Capital Employed at 96.79% in Q1 2026, 79.96% in Q4 2025, and 64.53% in Q3 2025.